Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02435199
Recruitment Status : Withdrawn
First Posted : May 6, 2015
Last Update Posted : August 26, 2015
Sponsor:
Collaborator:
Syneos Health
Information provided by (Responsible Party):
Spinifex Pharmaceuticals Pty Ltd

Brief Summary:

The study consists of two periods, the Screening Period (~3 weeks) and Treatment Period (12 weeks).

Eligibility for the study will be determined by Screening tests, physical examination/medical history, and fulfilment of eligibility criteria including assessment of pain completed during the Screening Period. Potential participants will be required to provide written informed consent prior to any study-specific Screening procedures being performed.

Following Screening assessments, patients will be randomized to receive either EMA401 300 mg BID or placebo.

Patient study visits during the Treatment Period are at the end of baseline/randomization visit, and end of Weeks 3, 6, 9, and 12, for assessments.


Condition or disease Intervention/treatment Phase
Diabetic Neuropathies Drug: EMA401 600mg Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy
Study Start Date : June 2015
Estimated Primary Completion Date : October 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: EMA401 600mg
2 X 150mg BID
Drug: EMA401 600mg
Placebo Comparator: Placebo
Placebo to match, 2 capsules BID
Drug: Placebo



Primary Outcome Measures :
  1. The efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN), as assessed by the difference in the weekly mean of the 24 hour average pain score, using an 11-point Numeric Rating Scale (NRS). [ Time Frame: Change from Baseline to Week 12 ]

Secondary Outcome Measures :
  1. The effect of EMA401 compared to placebo on the BPI-SF interference total score. [ Time Frame: Change from Baseline to Week 12 ]
  2. The effect of EMA401 compared to placebo on the weekly mean of the 24 hour worst NRS pain score. [ Time Frame: Change from Baseline to Week 12 ]
  3. The effect of EMA401 compared to placebo, on the Patient Global Impression of Change (PGIC). [ Time Frame: Change from Baseline to Week 12 ]
  4. The effect of EMA401 compared to placebo on the Brief Pain Inventory-Short Form (BPI-SF) average pain score. [ Time Frame: Change from Baseline to Week 12 ]
  5. The proportion of EMA401 patients achieving a ≥ 30% and a ≥ 50% reduction in weekly mean 24 hour average pain score compared to placebo (i.e., responder rates). [ Time Frame: Change from Baseline to Week 12 ]
  6. The effect of EMA401 compared to placebo on the Neuropathic Pain Symptom Inventory (NPSI). [ Time Frame: Change from Baseline to Week 12 ]
  7. The effect of EMA401 compared to placebo on the Insomnia Severity Index (ISI). [ Time Frame: Change from Baseline to Week 12 ]
  8. The safety and tolerability of EMA401 in patients with PDN as measured by number and severity of adverse events. [ Time Frame: Change from Baseline to Week 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with Type I or Type II diabetes mellitus with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least six months duration.
  • Be assessed as suffering from moderate to severe pain across the Screening Period. The assessment of moderate and severe pain will be made using an algorithm proprietary to Spinifex. The investigator/site staff will be informed immediately as to whether the patient is eligible or ineligible on the ePRO website based on the patient entering all relevant pain scores in the eDiary device.
  • Women of child bearing potential (WOCBP), must have a negative urine pregnancy test at the Screening visit (Visit 1) and within 72 hours prior to administration of IP.

Exclusion Criteria:

  • Patients taking any topical treatment for their PDN at the time of Screening Visit 2 will be excluded, including lidocaine plaster, capsaicin patch, and any other topical preparations of these or any other topical medications (e.g., aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for their PDN.
  • Have a blood pressure reading, after resting for at least five minutes, outside a systolic blood pressure range of 84 - 151 mmHg or a diastolic blood pressure > 95 mmHg. If the blood pressure is outside of the range, a repeat measurement can be taken after the patient has rested. The repeat measurement should be used as the screening value.
  • Have serum aspartate transaminase (AST), or alanine transaminase (ALT) levels > 1.5 x the upper limit of normal or have total bilirubin concentrations > 1.5 x the upper limit of normal at Screening (Visit 1).
  • Have hemoglobin A1c > 11 %.
  • Known history of, or positive laboratory results for hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection as defined by being seropositive for hepatitis B surface antigen (HBsAg), HCV antibodies or HIV antibodies respectively.
  • Have undergone neurolytic or neurosurgical therapy or use a neurostimulating device for PDN.
Layout table for additonal information
Responsible Party: Spinifex Pharmaceuticals Pty Ltd
ClinicalTrials.gov Identifier: NCT02435199    
Other Study ID Numbers: EMA401-011
First Posted: May 6, 2015    Key Record Dates
Last Update Posted: August 26, 2015
Last Verified: August 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases